225 related articles for article (PubMed ID: 34226077)
1. Managing Recurrent Metastatic Head and Neck Cancer.
Shaikh H; Karivedu V; Wise-Draper TM
Hematol Oncol Clin North Am; 2021 Oct; 35(5):1009-1020. PubMed ID: 34226077
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
[TBL] [Abstract][Full Text] [Related]
3. Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer.
Le X; Ferrarotto R; Wise-Draper T; Gillison M
J Natl Compr Canc Netw; 2020 Jul; 18(7):899-906. PubMed ID: 32634775
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
Front Immunol; 2021; 12():652054. PubMed ID: 34305889
[TBL] [Abstract][Full Text] [Related]
5. The biology of combination immunotherapy in recurrent metastatic head and neck cancer.
Yuan X; Yi M; Zhang W; Xu L; Chu Q; Luo S; Wu K
Int J Biochem Cell Biol; 2021 Jul; 136():106002. PubMed ID: 33962022
[TBL] [Abstract][Full Text] [Related]
6. Abscopal Effect Following Immunotherapy and Combined Stereotactic Body Radiation Therapy in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: A Report of Two Cases and Literature Review.
Choi JS; Sansoni ER; Lovin BD; Lindquist NR; Phan J; Mayo LL; Ferrarotto R; Su SY
Ann Otol Rhinol Laryngol; 2020 May; 129(5):517-522. PubMed ID: 31875405
[TBL] [Abstract][Full Text] [Related]
7. Recurrent and second primary squamous cell carcinoma of the head and neck: when and how to reirradiate.
Strojan P; Corry J; Eisbruch A; Vermorken JB; Mendenhall WM; Lee AW; Haigentz M; Beitler JJ; de Bree R; Takes RP; Paleri V; Kelly CG; Genden EM; Bradford CR; Harrison LB; Rinaldo A; Ferlito A
Head Neck; 2015 Jan; 37(1):134-50. PubMed ID: 24481720
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in head and neck squamous cell carcinoma: An updated review.
Parmar K; Mohamed A; Vaish E; Thawani R; Cetnar J; Thein KZ
Cancer Treat Res Commun; 2022; 33():100649. PubMed ID: 36279709
[TBL] [Abstract][Full Text] [Related]
9. Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma.
Specenier P; Vermorken JB
Expert Rev Anticancer Ther; 2018 Sep; 18(9):901-915. PubMed ID: 29999437
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapeutic Strategies for Head and Neck Cancer.
Buchwald ZS; Schmitt NC
Otolaryngol Clin North Am; 2021 Aug; 54(4):729-742. PubMed ID: 34116846
[TBL] [Abstract][Full Text] [Related]
11. Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma.
Ghosh S; Shah PA; Johnson FM
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887235
[TBL] [Abstract][Full Text] [Related]
12. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for Head and Neck Cancer.
Trivedi S; Sun L; Aggarwal C
Hematol Oncol Clin North Am; 2021 Oct; 35(5):1021-1037. PubMed ID: 34244017
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: A review of the literature.
Bossi P; Alfieri S; Strojan P; Takes RP; López F; Mäkitie A; Saba NF; Rodrigo JP; Bradford C; Suarez C; Zafereo M; Forastiere AA; Vermorken JB; Quer M; Sanabria A; Simo R; de Bree R; Rinaldo A; Ferlito A
Crit Rev Oncol Hematol; 2019 May; 137():84-91. PubMed ID: 31014517
[TBL] [Abstract][Full Text] [Related]
15. De novo metastatic head and neck squamous cell carcinoma: Why does locoregional control "always" matter?
Lorini L; Gili R; Salvestrini V; Morelli I; Smussi D; Petrelli F; Bonomo P; Bossi P
Oral Oncol; 2024 May; 152():106768. PubMed ID: 38552469
[TBL] [Abstract][Full Text] [Related]
16. Oncologic outcomes of salvage surgery and immune checkpoint inhibitor therapy in recurrent head and neck squamous cell carcinoma: A single-institution retrospective study.
Konuthula N; Do OA; Gobillot T; Rodriguez CP; Futran ND; Houlton J; Barber BR
Head Neck; 2022 Nov; 44(11):2465-2472. PubMed ID: 35930296
[TBL] [Abstract][Full Text] [Related]
17. Comparison of real-world outcomes following immunotherapy in recurrent or metastatic head and neck squamous cell carcinoma with outcomes of randomized controlled trials.
Yalamanchali A; Yang K; Roof L; Lopetegui-Lia N; Schwartzman LM; Campbell SR; Woody NM; Silver N; Koyfman S; Geiger JL; Yilmaz E
Head Neck; 2023 Apr; 45(4):862-871. PubMed ID: 36806299
[TBL] [Abstract][Full Text] [Related]
18. PET/CT prior to salvage surgery in recurrent head and neck squamous cell carcinoma.
Nøhr A; Gram SB; Charabi B; Tvedskov JF; Wessel I; Friborg J; Håkansson K; von Buchwald C; Fischer BM; Rasmussen JH
Eur Arch Otorhinolaryngol; 2019 Oct; 276(10):2895-2902. PubMed ID: 31297609
[TBL] [Abstract][Full Text] [Related]
19. JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer.
Yu Y; Lee NY
Future Oncol; 2019 Mar; 15(7):687-694. PubMed ID: 30461306
[TBL] [Abstract][Full Text] [Related]
20. Decision making in the management of recurrent head and neck cancer.
Ho AS; Kraus DH; Ganly I; Lee NY; Shah JP; Morris LG
Head Neck; 2014 Jan; 36(1):144-51. PubMed ID: 23471843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
